Targeting interleukin 4 receptor alpha on tumor-associated macrophages reduces the pro-tumor macrophage phenotype
Tumor-associated macrophages (TAMs) are an abundant tumor-promoting cell type in the tumor microenvironment (TME). Most TAMs exhibit a pro-tumor M2-like phenotype supportive of tumor growth, immune evasion, and metastasis. IL-4 and IL-13 are major cytokines that polarize macrophages to an M2 subset...
Main Authors: | Amber E. de Groot, Kayla V. Myers, Timothy E.G. Krueger, W. Nathaniel Brennen, Sarah R. Amend, Kenneth J. Pienta |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-10-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558622000574 |
Similar Items
-
A review of dupilumab in the treatment of atopic diseases
by: Quinn Thibodeaux, et al.
Published: (2019-09-01) -
Clinical efficacy of dupilumab in the treatment of severe chronic rhinosinusitis: The first case outside of a clinical trial
by: Matteo Trimarchi, et al.
Published: (2021-03-01) -
Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13
by: Corrado Pelaia, et al.
Published: (2022-06-01) -
Corneal Refractive Surgery Considerations in Patients on Dupilumab
by: Majid Moshirfar, et al.
Published: (2022-06-01) -
Assessment of the rapid effect of dupilumab in two cases of severe asthma comorbid with recurrent eosinophilic chronic rhinosinusitis after endoscopic sinus surgery
by: Yoshiro Kai, et al.
Published: (2021-08-01)